Chronic Remote Ischemic Conditioning in Vascular Cognitive Impairment: A Dose Escalation Study

NCT ID: NCT06179797

Last Updated: 2023-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-15

Study Completion Date

2023-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the dose-response of relevant blood biomarkers to remote ischemic conditioning in patients with age-related cerebral white matter hyperintensities on MRI, in preparation for a subsequent larger efficacy trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objective: The objective of this early phase study is to evaluate the dose-response of relevant blood biomarkers to remote ischemic conditioning in preparation for a subsequent larger efficacy trial. In addition, we will evaluate the tolerability and adherence to the treatment protocol.

Aim: We aim to measure blood biomarkers in response to daily remote ischemic conditioning (RIC) using a dose escalation study design in 40 patients with age-related cerebral white matter hyperintensities on MRI.

Hypothesis: We hypothesize that there will be a significant change in the biomarker levels in a dose dependent fashion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Age-related Cerebral White Matter Changes Cognition Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

randomized
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
concealed allocations and blinded laboratory personnel.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

sham

BP cuff bilateral arm compression to 50 mmHg.

Group Type SHAM_COMPARATOR

remote ischemic conditioning

Intervention Type DEVICE

suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.

dose 1

BP cuff bilateral arm compression to 50 mmHg above systolic BP for 2.5 minutes on/off for 4 cycles every other day.

Group Type ACTIVE_COMPARATOR

remote ischemic conditioning

Intervention Type DEVICE

suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.

dose 2

BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off for 4 cycles every other day.

Group Type ACTIVE_COMPARATOR

remote ischemic conditioning

Intervention Type DEVICE

suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.

dose 3

BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off once daily.

Group Type ACTIVE_COMPARATOR

remote ischemic conditioning

Intervention Type DEVICE

suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.

dose 4

BP cuff bilateral arm compression to 50 mmHg above systolic BP for 5 minutes on/off twice daily.

Group Type ACTIVE_COMPARATOR

remote ischemic conditioning

Intervention Type DEVICE

suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

remote ischemic conditioning

suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age ≥55 years
2. Head MRI in the past 6 months showing no more than moderate age related cerebral white matter changes (Fazekas score 0-2).
3. Able to walk without assistance \& independently perform basic activities of daily living.
4. Able to understand this study and agree for a valid consent.

Exclusion Criteria

Prior non-lacunar (cortical) stroke. 2. Unable to cooperate with the use of the conditioning device. 3. Confounding illness that might interfere with the interpretation of results (such as active malignancy or multiple sclerosis).

4\. Contraindication to transient arm ischemia in either arm (such as symptomatic peripheral artery disease).
Minimum Eligible Age

56 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Georgia Rehabilitation Institute

UNKNOWN

Sponsor Role collaborator

Augusta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Askiel Bruno

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Carol Smith, RN

Role: STUDY_DIRECTOR

Wellstar MCG Health

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wellstar MCG Health

Augusta, Georgia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Askiel Bruno, MD

Role: CONTACT

Phone: 706-721-1691

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Askiel Bruno, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1513705-3

Identifier Type: -

Identifier Source: org_study_id